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Many developing countries including Cameroon have mortality patterns that reflect high levels of 
infectious diseases and the risk of death during pregnancy and childbirth, in addition to cancers, 
cardiovascular diseases and chronic respiratory diseases that account for most deaths in the 
developed world. Several medicinal plants are used traditionally for their treatment. In this review, 
plants used in Cameroonian traditional medicine with evidence for the activities of their crude 
extracts and/or derived products have been discussed. A considerable number of plant extracts 
and isolated compounds possess significant antimicrobial, anti-parasitic including antimalarial, 
anti-proliferative, anti-inflammatory, anti-diabetes, and antioxidant effects. Most of the biologically 
active compounds belong to terpenoids, phenolics, and alkaloids. Terpenoids from Cameroonian 
plants showed best activities as anti-parasitic, but rather poor antimicrobial effects. The best 
antimicrobial, anti-proliferative, and antioxidant compounds were phenolics. In conclusion, many 
medicinal plants traditionally used in Cameroon to treat various ailments displayed good activities 
in vitro. This explains the endeavor of Cameroonian research institutes in drug discovery from 
indigenous medicinal plants. However, much work is still to be done to standardize methodologies 
and to study the mechanisms of action of isolated natural products.
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typhi infections). In the Cameroonian population, the lifetime 
risk of developing active tuberculosis once infected, in absence of 
HIV infection, is about 10%, meanwhile this increases tenfold in 
HIV infected individuals (Noeske et al., 2004). Malaria remains the 
leading cause of morbidity in Cameroon, and among the top five 
causes of mortality. Malaria represents approximately 45–50% of 
health consultations, and 23% of admissions (Edmondson, 2001). 
The unsatisfactory management of all diseases throughout the 
continent as well as in Cameroon, which allows partially treated 
and relapsed patients to become sequentially resistant, may play 
a significant role in the development of resistance for infectious 
diseases (Jones et al., 2008; McGaw et al., 2008). Effective treat-
ment of diseases is challenging for various reasons, including lack 
of accessibility and elevated expense of drugs and low adherence 
owing to toxicity of second-line drugs. It is all too likely that the 
emergence of resistance will be experienced in the future, exhaust-
ing the current arsenal of chemical defenses at our disposal. For this 
purpose, new drugs are urgently needed, and research programs 
into alternative therapeutics including medicinal plants investiga-
tions should be encouraged.
Biodiversity and protected area in cameroon
The biodiversity of Cameroon in term of protected land area, 
number of plant and some animals groups with threatened spe-
cies are summarized in Table 1 and Figure 1.
Cameroon has a rich biodiversity, with about 8,620 plants species 
and several animal groups (EarthTrends, 2003), encountered in both 
protected (about 8 %), and unprotected areas. About 155 plant spe-
cies are classified by the International Union for the Conservation 
puBlic health concern and diseases in cameroon
Health care is a basic service essential in any effort to combat pov-
erty, and is often promoted with public funds in Africa to achieve 
this aim (Castro-Leal et al., 2000). Nevertheless, curative health 
spending is not always well targeted to the poorest, representing 
about 50.5% of Cameroonian (Edmondson, 2001). Many devel-
oping countries including Cameroon have mortality patterns that 
reflect high levels of infectious diseases and the risk of death during 
pregnancy and childbirth, in addition to cancers, cardiovascular 
diseases and chronic respiratory diseases that account for most 
deaths in the developed world (WHO, 2009). In Cameroon, 3 out 
of 20 patients are able to buy prescribed drugs in hospitals and one 
out of every 1000 patients are able to see a specialist. Health care 
activities are coordinated by the Ministry of Public Health which 
receives the second highest budgetary allocation per ministry each 
year (Speak Clear Association of Cameroon, 2004). Health facilities 
are either run as government services or private services managed 
by the various churches and other private individuals. There are also 
traditional doctors that play a great role as far as the provisions of 
health care services are concerned. The major diseases associated 
with high degree of risk within the population include food or 
waterborne diseases (bacterial and protozoal diarrhea, hepatitis A 
and E, and typhoid fever), vector borne diseases (malaria and yellow 
fever), water contact diseases (schistosomiasis), respiratory diseases 
(meningococcal meningitis), and animal contact diseases (rabies) 
(Index mundi, 2008). Very often, there is a coexistence of many 
infectious diseases. Ammah et al. (1999) demonstrated that high 
proportion of patients (33%) had malaria coexisting with typhoid 
(Salmonella typhimurium, Salmonella paratyphi, and Salmonella 
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of Nature and Natural Resources (IUCN) as  threatened species. 
Threatened species used as medicinal plants include Thecacoris anno-
bonae Pax & K. Hoffm (Euphorbiaceae) (Cheek, 2004), Pausinystalia 
johimbe (K. Schum) (Rubiaceae) (Ngo Mpeck et al., 2004), Prunus afri-
cana (Hook. f.) Kalkm (Rosaceae) (Focho et al., 2009). Ancistrocladus 
korupensis D. W. Thomas & Gereau (Ancistrocladaceae), Carpolobia 
lutea G.Don (Polygalaceae), Dacryodes edulis (G. Don) H. J. Lam. 
(Burseraceae), Enantia chlorantha Oliv (Annonaceae), Garcinia man-
nii Oliv. (Clusiaceae), Garcinia cola Heckel (Clusiaceae), Gnetum afri-
canum Welw. (Gnetaceae), Invingia gabonensis Baill. (Irvingiaceae), 
Massularia acuminata (G. Don) Bullock (Rubiaceae), Pentaclethra 
macrophylla Benth. (Leguminosae), Baillonella toxisperma Pierre 
var. obovata Aubrév. & Pellegr. (Sapotaceae), Calamus deeratus 
Mann & Wendl. (Palmae), Cola acuminata (P.Beauv.) Schoot et 
Endl. (Sterculiaceae), Eremospatha macrocarpa (Mann & Wendl.) 
Wendl. (Palmae), Raphia regalis Becc. (Palmae), Raphia vinifera 
P.Beauv. (Palmae) and Ricinodendron heudelotti (Baill.) Pierre 
(Euphorbiaceae) (Koné, 1997). Protected zones include both land 
(3,741 ha) and marine areas (389 ha) (EarthTrends, 2003).
ethnoBotanical uses of medicinal plants in 
cameroon
Traditional healing plays an integral role in black African culture 
as it provides primary health care needs for a large majority (about 
80%) of the population (WHO, 2002). In Cameroon, there is a rich 
tradition in the use of herbal medicine for the treatment of several 
ailments. Unfortunately, the integration of traditional medicine 
in the health system is not yet effective, due to its disorganization 
(Nkongmeneck et al., 2007). However, the government strategies of 
health envisage the organization of traditional medicine in order 
to provide the main trends for the development and its integration 
(Anonymous, 2006). Adjanohoun et al. (1996) provided a useful 
review of the traditional use of medicinal plants in Cameroon, 
although much work remains to be done regarding the documen-
tation of existing ethnobotanical knowledge. Jiofack et al. (2010) 
also documented the traditional use of 289 plants species belonging 
to 89 families against 220 pathologies. Sixty eight percent of the 
documented plants are used to treat more than twenty important 
diseases. They are used as decoction, infusion, maceration, powder, 
powder mixtures, plaster, calcinations, and squeeze in water, boil-
ing, cooking with young cock or sheep meat or groundnut paste, 
direct eating, juice, fumigation, and sitz bath (Jiofack et al., 2010). 
The most recurrent diseases or disorders treated are typhoid, male 
sexual disorders, malaria, gonorrhea, gastritis, rheumatism, fever, 
dysentery, diarrhea, dermatitis, boils, cough, wounds, syphilis, steril-
ity, sexually transmitted diseases, ovarian cysts, and amoebiasis, with 
more than two hundred plants being used to cure these diseases or 
disorders (Jiofack et al., 2010).
investigation of the pharmacological potential of 
medicinal plants of cameroon
antimicroBial activity
Plants are widely used traditionally for the treatment of microbial infec-
tions. A review of the antimicrobial potential of Cameroon medicinal 
plants (Kuete, 2010a) reported more than 58 species in vitro active 
extracts or isolated compounds. Cut-off points for activity in term of 
IC
50
-values were set to 100 μg/ml for extract and 25 μM for compounds 
Table 1 | Biodiversity and protected area in Cameroon, Sub-Saharan 
Africa, and the World (Source: EarthTrends, 2003).
 Cameroon Sub-Saharan World 
  Africa
Total land areas 47,544 2,429,241 13,328,979
ProTECTEd ArEA (000 hA)
Extent of protected areas by IUCN Category (000 ha), 2003
 Total protected area 3,741 264,390 1,457,674 
 (Categories I–V)
 Marine and Littoral 389 − 417,970 
 protected areasa
 Protected areas as a 8.0% 10.9% 10.8% 
 percent of total land area
Biosphere reserves in 2002
 Number of sites 3 46 408
 Total area (000 ha) 876 − 439,000
NUmBEr ANd STATUS oF SPECIES
higher plants
 Total known species 8,260 – – 
 (number)
 Number of threatened 155 – 5,714 
 species
mammals
 Total known species 409 − – 
 (number)
 Number of threatened 40 − 1,137 
 species
Breeding birds
 Total known species 165 − – 
 (number)
 Number of threatened 15 − 1,192 
 specie
reptiles
 Number of total 210 − – 
 known species
 Number of threatened 1 − 293 
 species
Amphibians
 Number of total 171 − – 
 known species
 Number of threatened 1 − 157 
 species
Fish
 Number of total 138 − – 
 known species
 Number of threatened 27 − 742 
 species
IUCN, International Union for the Conservation of Nature and Natural Resources; 
Categories I, Nature Reserves, Wilderness, Areas; Categories II, National Parks; 
Category III, Natural monument; Category IV, Habitat/species management area; 
Category V, Protected landscape/seascape.
aMarine and littoral protected areas are not included in the “Total area protected” 
above; bIncludes IUCN categories I–V, marine and littoral protected areas are 
excluded from these totals.
(–): data not available.
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to bioactive compounds isolated from Cameroonian medicinal plants 
have shown that efflux by AcrAB-TolC pumps was one of the likely 
mechanisms of defense of Gram-negative bacteria to compounds 23 
and 47 (Kuete et al., 2010c).
antimalarial activity
In Cameroon, several plant species are used to treat malaria. A review 
on traditionally used plants reported up to 217 species (Titanji et al., 
2008). Some of these plants were screened in vitro for their activity 
against P. falciparum and more than 100 bioactive compounds were 
isolated (Titanji et al., 2008), most of which, however, showed only 
low or modest antimalarial activities. In the present review, we focus 
only on plant extract and compounds that exhibited considerably 
high activities. The proposed cut-off points for in vitro activity of 
antimalarial extracts based on their IC
50
 values can be categorized as 
follows: IC
50
 < 0.1 μg/ml (very good); 0.1–1 μg/ml (good); 1.1–10 μg/
ml (good to moderate); 11–25 μg/ml (weak), 26–50 (very weak), 
>100 μg/ml (inactive) (Willcox et al., 2004a). The following inhibi-
tion percentages were proposed for in vivo activity of antimalarial 
extracts at a fixed dose of 250 mg/kg/day: 100–90% (very good 
activity); 90–50% (good to moderate); 50–10% (moderate to weak); 
0% (inactive) (Willcox et al., 2004a). Several plant extracts from 
Cameroonian medicinal plants were reported for their antimalarial 
activities (Table 2), the most active (IC
50
 < 1 μg/ml) being that from 
Enantia chlorantha (Boyom et al., 2009).
Some isolated compounds were also reported for their antimalar-
ial activities (Table 2). An IC
50
 of 1.5 μM was chosen as cut-off point 
for several compounds (Calas et al., 1997). The threshold for in vitro 
chloroquine resistance has been defined as IC
50
 > 100 nM (Ringwald 
et al., 1996). According to Mahmoudi et al. (2006), compounds with 
IC
50
 > 5 μM were considered as inactive against parasite develop-
ment, compounds with IC
50
 between 0.06 and 5 μM being active, 
and values of IC
50
 < 0.06 μM implying the drugs to be very toward 
P. falciparum. We will take into consideration up to IC
50
 < 20 μg/
ml to report on the activity of antimalarial  compounds isolated 
from Cameroonian medicinal plants. So far, active compounds iso-
lated belong to three main groups of secondary metabolites, terpe-
(Cos et al., 2006). However, in the case of antimicrobial evaluation 
of extracts and compounds, determination of IC
50
 is not the optimal 
parameter for significance, most of the reported data being given as 
MIC values. Kuete (2010a) also set the bar as follows for extract: signif-
icant (MIC < 100 μg/ml), moderate (100 < CMI ≤ 625 μg/ml) or weak 
(CMI > 625 μg/ml). For compounds, this stringent endpoints criteria 
were: significant (MIC < 10 μg/ml), moderate (10 < MIC ≤ 100 μg/ml), 
and low or negligible (MIC > 100 μg/ml) (Kuete, 2010a). More than 
50 microorganisms were found to be sensitive to such extracts and 
significant activity with minimally inhibiting concentrations (MIC) 
of less than 100 μg/ml (Kuete, 2010a). Some of the extracts includ-
ing those from Bersama engleriana, Dorstenia angusticornis, Dorstenia 
barteri, Diospyros canaliculata, Diospyros crassiflora, Newbouldia laevis, 
and Ficus cordata exhibited a wide range of activity on both bacteria 
and fungi (Kuete, 2010a).
Some of the bioactive compounds such as diospyrone (23), crassi-
florone (24), newbouldiaquinone (25), newbouldiaquinone A (26), 
laurentixanthone A (30), laurentixanthone B (31), smeathxanthone 
B (32), cheffouxanthone (33), bangangxanthone A (34), globulixan-
thone C (35), D (36) and E (37), moracin T (43), and U (44), nkolbi-
sine (59), norerythrosuaveolide (60), were isolated and characterized 
for the first time from Cameroonian medicinal plants (Kuete, 2010a). 
Other compounds such as plumbagin (27), lapachol (28) (found to 
be inactive in vivo in some cases), isobavachalcone (47), 4-hydrox-
ylonchocarpin (48), kanzonol C (49) exhibited interesting activities 
and were suggested as potential candidates for new antimicrobial 
drug (Kuete, 2010a). Though compound 28 is known to possess good 
antimicrobial activity in vitro, it will be necessary to assess its in vivo 
efficacy. However this compounds was active in vitro against intracel-
lular amastigotes of Leishmania braziliensis and inactive in vivo using 
hamster infected model (Lima et al., 2004). Thecacoris cf. annobonae 
Pax & K. Hoffm (Euphorbiaceae) exhibited significant antimicrobial 
(MIC < 10 μg/ml) activities against Mycobacterium tuberculosis H37Rv, 
Bacillus cereus and Pseudomonas aeruginosa (Kuete et al., 2010b). The 
extract from T. annobonae was reported to induce E. coli death through 
the  inhibition of H+-ATPase-mediated proton pumping (Kuete et al., 
2010b). Investigations the mode of resistance of the microorganisms 
FIgUrE 1 | Portion of land area protected (A) by IUCN Category (2003) and threatened species (B) (2002–2003) in Cameroon (Source: EarthTrends, 2003). IUCN, 
International Union for the Conservation of Nature and Natural Resources; Categories I, nature reserves, wilderness, areas; Categories II, national parks; Category III, 
natural monument; Category IV, habitat/species management area; Category V, protected landscape/seascape.
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Table 2 | Plants used in Cameroon to treat malaria, with evidence of their activities.
Family Speciesa Traditional treatment Plant part 
used
Bioactive (or potentially 
active) compoundsb
Screened activity
Acanthaceae Thomandersia 
hensii De Wild 
and Th. Dur (LB Th 
0301)
Malaria, diarrhea, colitis, 
furuncles, abscesses, 
syphilis, ulcers, urogenital 
disorders, intestinal parasites, 
debility, tiredness, edema, 
rheumatism, eye 
inflammations (Letouzey, 
1985; Ngadjui et al., 1994).
Bark, leaves, 
pulp, sap, 
roots
Not identified IC50 < 30 μg/ml reported for 
hexane extract from the stem 
bark on P. falciparum W2 
(Indochina I/CDC) chloroquine-
resistant strain (Bickii et al., 
2007b)
Annonaceae Uvariopsis 
congolana (De 
Wild) Fries 
(37016/HNC)
Malaria (Boyom et al., 2009) Bark, leaves Not identified, but plants of 
this family were reported to 
contain acetogeninsc
IC50 < 5 μg/ml reported for the 
crude extract from the leaves and 
bark on P. falciparum strain W2 
(Boyom et al., 2009)
Polyalthia oliveri 
Engl. (19416 SRF/
Cam)
Malaria (Boyom et al., 2009) Bark IC50 < 5 μg/ml reported for the 
crude extract from the bark on P. 
falciparum strain W2 (Boyom 
et al., 2009)
Enantia 
chlorantha Oliv. 
(32065/SRF/Cam)
Malaria (Boyom et al., 2009) Bark, leaves Not identified IC50 < 1 μg/ml reported with the 
crude extract from the leaves and 
bark on P. falciparum strain W2 
(Boyom et al., 2009)
Apocynaceae Picralima nitida 
Stapf (LB Pn 
0301) 
Malaria, diarrhoea, intestinal 
worms, gonorrhoea, 
inflammation (Letouzey, 
1985; Ezeamuzie et al., 1994; 
Fakeye et al., 2000)
Bark, roots, 
seeds; fruits
Not identified IC50 < 30 μg/ml reported for the 
methanol and dichloromethane–
methanol 1:1 extracts from the 
seeds and bark on P. falciparum 
W2 (Indochina I/CDC) chloroquine-
resistant strain (Bickii et al., 
2007b)
Euphorbiaceae Croton 
zambesicus 
Muell. Arg. (8204/
SRFCam)
Malaria (Boyom et al., 2009) Bark Not identified IC50 < 10 μg/ml reported for the 
crude extract from the bark on P. 
falciparum strain W2 (Boyom 
et al., 2009)
Neoboutonia 
glabrescens Müll. 
Arg. Prain (7433/
SRFCam)
Malaria (Boyom et al., 2009) Bark, leaves Not identified IC50 < 10 μg/ml reported for the 
crude extract from the leaves and 
bark on P. falciparum strain W2 
(Boyom et al., 2009)
Guttiferae Symphonia 
globulifera Linn f. 
(50788/HNC)
Stomach and skin aches, 
laxative for pregnant women, 
general tonic, Malaria 
(Aubreville, 1950; Irvine, 
1961; Ngouela et al., 2006). 
Bark Gaboxanthone (38); 
symphonin (39); globuliferin 
(40); guttiferone A (50) 
(Ngouela et al., 2006).
IC50 <20 μM on P. falciparum 
reported for compounds 38–40 
and 50 (Ngouela et al., 2006).
Lauraceae Beilschmiedia 
zenkeri Engl.
Not reported Bark 5-Hydroxy-7,8-
dimethoxyflavone; 
pipyahyine; betulinic acid 
(Lenta et al., 2009)
IC50 <5 μM on chloroquine-
resistant P. falciparum reported for 
pipyahyine (Lenta et al., 2009)
Meliaceae Entandrophragma 
angolense 
Welwitsch C.D.C. 
(29933/HNC)
Malaria (Bickii et al., 2007a) Bbark 22-Hydroxyhopan-3-one; 
24-methylenecycloartenol 
(8); tricosanoic acid; 
methylangolensate; 
7α-acetoxydihydronomilin 
(9); 7α-obacunylacetate (10) 
(Bickii et al., 2007a)
IC50 < 20 μg/ml on P. falciparum 
W2 strain reported for 
compounds 8–10. The 
dichloromethane – methanol (1:1) 
extract of the stem bark of that 
plant exhibited IC50 of 18.8 μg/ml 
(Bickii et al., 2007a)
(Continued)
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Family Speciesa Traditional treatment Plant part 
used
Bioactive (or potentially 
active) compoundsb
Screened activity
Khaya 
grandifoliola 
C.D.C. (PM 
098/95/HNC)
Malaria (Obih et al., 1985; 
Bray et al., 1990; Weenen 
et al., 1990).
Bark and 
seeds
Methylangolensate (1); 
6-methylhydroxyangolensate 
(2); gedunin (3); catechin; 
7-deacetylkhivorin (4); 
1-deacetylkhivorin (5); 
swietenolide (6); 
6-acetylswietenolide (7) 
(Bickii et al., 2000)
IC50 < 20 μg/ml on P. falciparum 
W2 strain reported for bark and 
seeds extracts; compounds 1–7. 
Compound 3 exhibited an additive 
effect when combined with 
chloroquine (Bickii et al., 2000)
Turreanthus 
africanus
Malaria and other fevers 
(Zhou et al., 1997)
Bark, seeds, 
leaves
16-oxolabda-8 (17), 
12(E)-dien-15-oic acid; 
methyl-14, 15-epoxylabda-8 
(17), 12(E)-diene-16-oate; 
turreanin A (Ngemenya et al., 
2006)
None of the active compounds 
exhibited IC50 < 20 μg/ml on P. 
falciparum F 32, chloroquine 
sensitive strain (Ngemenya et al., 
2006)
Moraceae Artocarpus 
communis J.R. & 
G. Forst (43982 
HNC)
Malaria (Boyom et al., 2009) Bark, leaves Not identified IC50 < 10 μg/ml reported for the 
crude extract from the leaves and 
bark on P. falciparum strain W2 
(Boyom et al., 2009)
Dorstenia 
convexa De Wild 
(53450 HNC)
Malaria (Boyom et al., 2009) Twigs Not identified IC50 < 10 μg/ml reported with the 
crude extract from the twigs on P. 
falciparum strain W2 (Boyom 
et al., 2009)
Zingiberaceae Aframomum 
zambesiacum 
(Baker) K. Schum 
(37737HNY)
Malaria (Kenmogne et al., 
2006)
Seeds Aulacocarpin A (11); 
aulacocarpin B; 
3-deoxyaulacocarpin A (12); 
methyl-14n,15-epoxy-3b-
hydroxy-8(17),12-elabdadien-
16-oate; galanolactone; 
zambesiacolactone A (13); 
zambesiacolactone B (14); 
aframodial (Kenmogne et al., 
2006)
IC50 < 20 μM on P. falciparum 
reported for compounds 11–14 
(Kenmogne et al., 2006)
Reneilmia 
cincinnata (K. 
Schum.) Bak.
Malaria (Tchuendem et al., 
1999)
Fruits Oplodiol (17); 5E,10(14)-
Germacradien-1β,4β-diol 
(16); 1(10)E,5E-
germacradien-4β-ol (15) 
(Tchuendem et al., 1999)
IC50 < 5 μM reported on P. 
falciparum D6 and W2 strains for 
compounds 15–17 on P. 
falciparum D6 strain (Tchuendem 
et al., 1999
aHNC or SRFK: Cameroon National herbarium code; LB, Laboratory of Botany, Yaoundé.
bCompounds characterized for the first time in Cameroonian medicinal plant are underlined.
cAnnonaceous acetogenins are inhibitors of complex I (NADH: ubiquinone oxidoreductase) in mitochondrial electron transport systems (Lewis et al., 1993), and 
NADH oxidase of plasma membranes (Morré et al., 1995), two enzymes found in Plasmodium falciparum.
Table 2 | Continued
noids (Figure 2), phenolics (Figure 3), and alkaloids (Figure 4). 
Antimalarial terpenoids including sesqui-, di-, and triterpenoids 
are the most frequently isolated compounds from Cameroonian 
plants. Several natural products were reported as being active against 
Plasmodium falciparum, with IC
50
 values below 20 μg/ml, including 
methylangolensate (1); 6-methylhydroxyangolensate (2); gedunin 
(3); 7-deacetylkhivorin (4); 1-deacetylkhivorin (5); swietenolide (6); 
6-acetylswietenolide (7) (Bickii et al., 2000); 24-methylenecycloar-
tenol (8); 7α-acetoxydihydronomilin (9); 7α-obacunylacetate (10) 
(Bickii et al., 2007a); aulacocarpin A (11); 3-deoxyaulacocarpin A 
(12); zambesiacolactone A (13), and B (14) (Kenmogne et al., 2006); 
1(10)E,5E-germacradien-4β-ol (15); 5E,10(14)-germacradien-
1β,4β-diol (16); oplodiol (17) (Tchuendem et al., 1999); IC
50
 < 5 μg/
ml were obtained for compounds 3 (1.25 μg/ml), and 10 (2 μg/ml) 
(Bickii et al., 2000, 2007a), while values below 5 μM were recorded 
for compounds 12 (4.97 μM) (Kenmogne et al., 2006), 15 (1.54 μM); 
16 (1.63 μM) and 17 (4.17 μM) (Tchuendem et al., 1999).
Phenolic compounds (Figure 3) such as gaboxanthone (38); 
symphonin (39); globuliferin (40); guttiferone A (50) (Ngouela 
et al., 2006) also exhibited antimalarial activities when tested on 
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2005). It is estimated that about 200 million people worldwide are 
currently affected by schistosomiasis, a disease caused by flatworms 
belonging to the genus Schistosoma. The disease is usually chronic 
and debilitating, with severe consequences on the urinary tract 
where S. haematobium is the organism involved and major dam-
age to the intestinal tract where S. mansoni, S. intercalatum or S. 
japonicum are involved (Jatsa et al., 2009). In humans, Toxoplasma 
infections are widespread and lead to severe diseases in individu-
als with immature or suppressed immune system. Consequently, 
toxoplasmosis became one of the major opportunistic infections 
of the AIDS epidemic (Luft and Remington, 1992). Toxoplasmosis 
also affects T. gondii-negative women during pregnancy and is a 
serious threat for embryos. Despite the huge impact of these para-
sitic diseases, the drugs used for their treatment are often toxic, 
marginally effective, administered by injection only, expensive, 
and/or compromised by the development of resistance (Ouellette 
et al., 2004; Croft et al., 2005). Only few researchers in Cameroon 
focused on antitrypanosomal and antileishmanial compounds 
from medicinal plants. Available published data on traditionally 
used medicinal plants are compiled in Table 3. Herein, similar 
cut-off points as indicated above for antimalarials have been 
considered for activities against trypanosomal, leishmanial and 
schistosomal pathogens. Compounds with good antileishmanial 
activities were isolated from Garcinia lucida (Clusiaceae), with IC
50
 
P. falciparum. IC
50
 values below 5 μg/ml were reported with com-
pounds 38 (3.53 μM); 39 (1.29 μM); 40 (3.86 μM) and 50 (3.17 μM) 
(Ngouela et al., 2006). Few alkaloids from Cameroonian medicinal 
plants (Figure 4) were characterized. For example, pipyahyine (61) 
exhibited good activity (IC
50
 < 5 μM) toward chloroquine-resistant 
P. falciparum (Lenta et al., 2009).
Studies dealing with the mechanisms of action of antimalarial 
compounds are still limited. However, some of the extracts from 
Cameroonian medicinal plants such as those from Annonaceae 
species were suggested to exert their antiplasmodial activity by 
the inhibition of vital parasitic enzymes such as cysteine proteases 
(Boyom et al., 2009).
other anti-parasitic activities
Parasitic trypanosomatids cause a number of important diseases, 
including human African trypanosomiasis, Chagas disease, and 
leishmaniasis. More than 60 million people living in 36 sub-Saharan 
Africa countries are at risk of contracting sleeping sickness, caused 
by Trypanosoma brucei gambiense and T. b. rhodesience (WHO, 
2007). It is estimated that currently 300,000–500,000 people were 
infected in 2001, with 50,000 deaths  annually (Fairlamb, 2003; 
WHO, 2007). Leishmania species cause a spectrum of disease rang-
ing from self-healing cutaneous lesions to life-threatening visceral 
infections, with 2 million new cases occurring annually (WHO, 
FIgUrE 2 | Bioactive terpenoids. Activity [(a) antimalarial, (b) anti-inflammatory, (c) antitrypanosomal]; Glc, glucosyl group; Ac, acetyl group.
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values of 2.0 and 6.6 μg/ml, respectively, for dihydrochelerythrine 
(62) and 6-acetonyldihydrochelerythrine (63) against L. dono-
vani (Fotie et al., 2007). Significant antitrypanosomal activities 
were also reported for stigmastane derivatives, vernoguinosterol 
(21) and vernoguinoside (22) (Figure 2) isolated from Vernonia 
guineensis (Asteraceae), against bloodstream trypomastigotes of 
Trypanosoma brucei rhodesiense with IC
50
 values ranging from 3 
to 5 μg/ml (Tchinda et al., 2002).
anti-proliferative activity
Screenings of medicinal plants used as anticancer drugs has pro-
vided modern medicine with effective cytotoxic pharmaceuticals. 
More than 60% of the approved anticancer drugs in United State 
of America (from 1983 to 1994) were from natural origin (Stévigny 
et al., 2005; Newman and Cragg, 2007). The diversity of the biosyn-
thetic pathways in plants has provided a variety of lead structures 
that have been used in drug development. In this last decade, inves-
tigations on natural compounds have been particularly successful in 
the field of anticancer drug research. Early examples of anticancer 
agents developed from higher plants are the antileukemic alkaloids 
(vinblastine and vincristine), which were both obtained from the 
Madagascar periwinkle (Catharanthus roseus) (Voss et al., 2005). 
The development of the highly automated bioassay screening based 
on colorimetric methods that quantified the proliferation of cell 
culture (Mosmann, 1983) of a huge number of plants extracts have 
permitted to find that many plant families (Guittiferae, Rubiaceae, 
Apocynaceae, Euphorbiaceae, Solanaceae, etc.) exhibited a great 
potential of anti-proliferative activity (Hostettmann et al., 2000; 
Whelan and Ryan, 2003). A large number of plant extracts have 
shown the in vitro and in vivo antitumor activities (Hostettmann 
et al., 2000). In the US NCI plant screening program, a crude extract 
is generally considered to have in vitro cytotoxic activity if the IC
50
 
value following incubation between 48 and 72 h, is less than 20 μg/
ml, while it is less than 4 μg/ml for pure compounds (Boik, 2001). 
This cut-off point for good cytotoxic compound has also been 
defined as 10 μM (Brahemi et al., 2010). Despite the exceptional 
biodiversity of Africa, few scientific studies have been carried out in 
the continent regarding the anti-proliferative properties of medici-
nal plants. However, some Cameroonian plants and derived natural 
products were tested for their anti-proliferative effects. Five medici-
nal plants widely used in cancer treatment, Sida acuta, Sida cordi-
folia, Sida rhombilifolia, Urena lobata, Viscum album, were recently 
screened for their cytoxicity against Hep G2  hepatocarcinoma cells 
rather showed moderate anti-proliferative effects (Pieme et al., 
2010). However, studies based on the inhibition of Crown Gall 
tumors revealed pronounced tumor reducing activity of extracts 
from the roots and leaves from Bersama engleriana (Kuete et al., 
2008). An IC
50
 of 27.16 μg/ml was reported for Antiaris africana 
in DU-145 prostate cancer cells, while even better activity (IC
50
 of 
13.84 μg/ml) was recorded in Hep G2 hepatocarcinoma cells (Kuete 
et al., 2009). One of the most active compounds isolated from 
A. africana, 3,39-dimethoxy-49-O-β-d-xylopyronosylellagic acid 
(58) (Figure 3) exhibited considerable anti-proliferative activities 
toward HepG2 (IC
50
 of 3.84 μg/ml) and DU-145 (IC
50
 of 6.24 μg/
ml) cells (Kuete et al., 2009). Compound 28, the main constituent of 
a Cameroonian medicinal plant, Newbouldia leavis (Bignoniaceae) 
was found to be very active against DU-145 cells with an IC
50
 of 
64.59 nM (Eyong et al., 2008). Wighteone (53) and alpinumiso-
flavone (54) isolated from Erythrina indica (Leguminosae) were 
reported to be cytotoxic (effective dose of 0.78 and 4.13 μg/ml, 
respectively) when tested against KB nasopharyngeal cancer cells 
(Nkengfack et al., 2001). Globulixanthones A (41) and B (42) 
isolated for the first time in the Cameroonian medicinal plant, 
Symphonia globulifera L. f. (Clusiaceae), showed good anti-prolif-
erative activities against human KB cells, with IC
50
 values of 2.15 
and 1.78 μg/ml, respectively (Nkengfack et al., 2002). Compound 
FIgUrE 3 | Bioactive phenolics [quinones (23–29), xanthones (30–42), 
arylbenzofurans (43–46)]. Activity [(a) antimicrobial, (b) anti-inflammatory, (c) 
antimalarial, (d) anti-proliferative, (e) antioxidant]. [Chalcones (47–49), 
benzophenone (50), flavone (51–52), isoflavones (53–56), pterocarpene (57), 
ellagic acid derivative (58)]. Activity [(a) antimicrobial, (b) anti-inflammatory, 
(c) antimalarial, (d) anti-proliferative, (e) antioxidant].
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47 isolated from Dorstenia barteri (Ngameni et al., 2007) and D. 
turbinata (Ngameni et al., 2009) was cytotoxic toward a wide spec-
trum of tumor cell lines, including ovarian carcinoma OVCAR-8 
cells, prostate carcinoma PC3 cells, breast carcinoma MCF-7 cells, 
and lung carcinoma A549 cells (Jing et al., 2010). Compound 47 
significantly ablated Akt phosphorylation at Ser-473 and Akt kinase 
activity in cells, which subsequently led to inhibition of Akt down-
stream substrates and evoked significant levels the mitochondrial 
pathway of apoptosis (Jing et al., 2010). Nishimura et al. (2007) 
demonstrated that compound 47 induced apoptotic cell death with 
caspase-3 and -9 activation and Bax upregulation in neuroblastoma 
cell lines. Compound 47 inhibited MMP-2 secretion from U87 
glioblastoma cells (Ngameni et al., 2007). Compounds 48 and 49 
also isolated from Dorstenia turbinata (Moraceae), inhibited the 
matrix metalloproteinase (MMP)-2 secretion from brain tumor-
derived glioblastoma cells (Ngameni et al., 2006).
anti-inflammatory and analgesic activities
Pain is one common health problem with substantial socioeconomic 
impact because of its high incidence. It is a symptom of many dis-
eases and it is estimated that 80–100% of the population experience 
back pain at least once in the life time (Jain et al., 2002). The treat-
ment of pain requires analgesics including inflammatory products. 
Hence, most of the non-steroidal anti-inflammatory agents also 
have analgesic activity. The inhibition of prostaglandin E2 (PGE2) 
and nitric oxide (NO) production has been proposed as a potential 
therapy for different inflammatory disorders (Nowakowska, 2007). 
Although, many analgesics and anti-inflammatory agents are present 
on the market, modern drug therapy is associated with some adverse 
effects like gastrointestinal irritation (Jain et al., 2002; Osadebe and 
Okoye, 2003), fluid retention, bronchospasm, and prolongation of 
bleeding time. Therefore, it is necessary to search for new drugs 
with less adverse effects. Medicinal plants have been used for the 
development of new drugs and continue to play an invaluable role 
for the progress of drug discovery (Raza et al., 2001). Plant extracts 
can be an important source of safer drugs for the treatment of pain 
and inflammation. Several medicinal plants and derived products 
were screened for their anti-inflammatory and analgesic proper-
ties (Table 4). Bark extract as well as terpenoids from Combretum 
molle (Combretaceae), β-d-glucopyranosyl 2α,3β,6β-trihydroxy-
23-galloylolean-12-en-28-oate (18); combregenin (19); arjungenin 
(20) (Figure 2) showed good activities against carrageenan-induced 
paw edema in rat (Ponou et al., 2008). A naphthoquinone, 2-acetyl-
7-methoxynaphthol[2,3-b]furan-4,9-quinone (29), isolated from 
the anti-inflammatory crude extract of Millettia versicolor inhib-
ited 12-O-tetradecanoylphorbol 13-acetate (TPA)-induced acute 
ear edema and phospholipase A
2
 (PLA
2
) acute mouse paw edema 
(Fotsing et al., 2003). Isoflavones, griffonianone D (55) (Figure 3) 
isolated from Millettia griffoniana (Yankep et al., 2003), warangalone 
(56) isolated from the bark of Erythrina addisoniae (Talla et al., 
2003), and erycristagallin (57) isolated from the root of Erythrina 
mildbraedii (Njamen et al., 2003), showed marked effectiveness as 
an anti-inflammatory on PLA
2
-induced paw edema and on TPA-
induced ear edema in mice (Njamen et al., 2003; Talla et al., 2003). 
Flavonoids sigmoidin A (51) and B (52) (Figure 3) isolated from 
Erithrina sigmoidea, and compound 57 were also effective against 
TPA-induced ear edema (Njamen et al., 2003, 2004).
anti-diaBetic activity
Diabetes mellitus is a group of metabolic disorders with one com-
mon manifestation, hyperglycemia (WHO, 1980, 1985). Chronic 
hyperglycemia causes damage to eyes, kidneys, nerves, heart, and 
blood vessels (Mayfield, 1998). It is caused by inherited and/or 
acquired deficiency in insulin production of the pancreas, or by 
unresponsiveness toward insulin. It results either from inadequate 
secretion of hormone insulin, an inadequate response of target cells 
to insulin, or a combination of these factors (Malviya et al., 2010). 
Diabetes is projected to become one of the world’s main disablers 
and killers within the next 25 years (Malviya et al., 2010). The man-
agement of diabetes is a global problem and a  successful treatment 
FIgUrE 4 | Bioactive alkaloids. Activity [(a) antimicrobial, (b) antimalarial, (c) antileishmanial].
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Table 3 | Plants used in Cameroon to treat some parasitic infections with evidence of their activities.
Family Speciesa Traditional treatment Plant part 
used
Bioactive (or potentially 
active) compoundsb
Screened activityC
Annonaceae Polyalthia 
suaveolens Engl. 
& Diels (1227/
SRFK)
Rheumatic pains (Surville, 
1955)
Not 
specified
Polyveoline; 3-O-acetyl 
greenwayodendrin; polysin; 
greenwayodendrin-3-one 
(Ngantchou et al., 2010)
Antitrypanosomal activity: weak 
activity for polyveoline (IC50: 
32 μM); 3-O-acetyl 
greenwayodendrin (IC50: 
54 μM); mixture of polysin and 
greenwayodendrin-3-one (IC50: 
18 μM) against T. brucei 
(Ngantchou et al., 2010)
Asteraceae Vernonia 
guineensis Benth. 
(BUD 301)
Anthelmintic, anti-poison, 
malaria, jaundice (Iwu, 1993)
Leaves Vernoguinosterol (21); 
vernoguinoside (22) (Tchinda 
et al., 2002)
Antitrypanosomal activity: 
significant for compounds 22 
and 23 against four strains of 
bloodstream trypomastigotes T. 
b. rhodesiense with IC50 values 
in the range 3–5 mg/ml (Tchinda 
et al., 2002)
Guttiferae Garcinia lucida 
Vesque (5768/
HNC)
Gastric infections, anti-poison 
(Nyemba et al., 1990)
Bark Dihydrochelerythrine (62); 
6-acetonyldihydrochelerythrine 
(63); lucidamine A (Fotie et al., 
2007)
Antileishmanial activity: 
Significant activity for 
compounds 62 and 63 and 
moderate for lucidamine A 
against L. donovani. Also, 100% 
Inhibition of promastigote at 
100 μg/ml were reported for all 
the above compounds (Fotie 
et al., 2007)
Meliaceae Turraeanthus 
africanus (Welw. 
ex C.D.C.) Pellegr 
(8233/HNC)
Asthma, stomachache, 
intestinal worms, and 
inflammatory diseases 
(Ekwalla and Tongo, 2003)
Aerial parts, 
roots
Turraeanthin C; sesamin 
(Vardamides et al., 2008)
Antitoxoplamal activity: 
Moderate activity for 
turraeanthin C and low activity 
for crude bark extract and 
sasamin. Inhibition of parasite 
growth at 10 μg/ml was found 
to be 55% for turraeanthin C, 
20% for sesamin and 40% for 
crude extract (Vardamides et al., 
2008)
Verbenaceae Clerodendrum 
umbellatum Poir 
(7405/HNC)
Epilepsy, headache, intestinal 
helminthiasis, irregular 
menstruation, infective 
dermatitis, asthma, 
metaphysical powers, 
whitlow, vulvovaginitis 
(Adjanohoun et al., 1996; Jatsa 
et al., 2009)
Not 
specified
Not identified but, flavonoids, 
saponins, saponosides, 
tannins, and triterpenes were 
detected in the leaves 
aqueous extract (Jatsa et al., 
2009)
Antischistosomal activity: 
100 % reduction rate reported 
for mice infected with S. 
mansoni when treated with 
160 mg/kg body weight of 
aqueous leaves extract (Jatsa 
et al., 2009)
aHNC or SRFK: Cameroon National herbarium code; BUD, Herbarium of the Botany Department of the University of Dschang, Cameroon).
bCompounds characterized for the first time in Cameroonian medicinal plant are underlined.
cScreened activity: Leishmania donovani (L. donovani); Schistosoma mansoni (S. mansoni); Toxoplasma gondii (T. gondii); Trypanosoma brucei rhodesiense (T. b. 
rhodesiense); Trypanosoma brucei (T. brucei).
has not yet been discovered. The total number of  persons affected 
globally is projected to rise from 246 million in 2007 to 380 mil-
lion in 2025, if prevention measures will not be scaled up (Bennett, 
2007). In Africa, the number of diabetic patients in 2006 was 
10.4 million, and it is expected to increase to 18.7  million in 2025. 
The annual mortality linked to diabetes worldwide is  estimated 
to be above one million. In Cameroon, the prevalence of diabetes 
increased from 2% in 1998 (in a study supported by the World 
Diabetes Foundation, WDF) to 5% in 2003 and 6.5% in 2007 (in 
another WDF study, Walgate, 2008). Medicinal plants have been 
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Family Speciesa Traditional treatment Plant part 
used
Bioactive (or 
potentially active) 
compoundsb
Screened activityc
Acanthaceae Acanthus 
montanus 
(Nees) T. 
Anderson 
(1652/
SRF61CAM)
Cough, hypertension, skin 
infection, boil, witches, 
dysmenorrhoea, pain, epilepsy, 
miscarriages, heart troubles, 
rheumatic pain, syphilis (Burkill, 
1985; Adjanohoun et al., 1996; 
Babu et al., 2001; Noumi and 
Fozi, 2003; Igoli et al., 2005; 
Nana et al., 2008)
Leaves Not identified Leave extract showed analgesic 
and anti-inflammatory properties 
and the proposed mechanism 
was the inhibition of the 
prostaglandins pathway at 
200 mg/kg in rats. Also, this 
extract at 200 mg/kg body weight 
in rats reduced carrageenan-
induced edema, and formalin-
induced pain (Asongalem et al., 
2004).
Anacardiaceae Sclerocarya 
birrea (A. Rich.) 
Hochst (7770/
HNC)
Boils and blood circulation 
problems, rheumatism, 
infectious diseases, 
inflammation (Mojeremane and 
Tshwenyane, 2004; Fotio et al., 
2009)
Bark Not identified Bark extract inhibited albumin-
induced paw edema (Ojewole, 
2004), Formalin- or Freund’s 
adjuvant (CFA)-carrageenan-, 
histamine, or serotonin-induced 
paw edema (Fotio et al., 2009) in 
rats
Caesalpiniaceae Erythrophleum 
suaveolens, 
Guillemin & 
Perrottet 
(HN001AD)
Anti-poison, dermatitis, 
infectious disease, convulsion, 
inflammation due to snake bite, 
cardiac problems, headaches, 
migraines edema, rheumatism, 
asthma (Dalziel, 1937; 
Bouquet, 1969; Leiderer, 1982; 
Neuwinger, 1998)
Bark Not identified Extract from the bark and 
fractions at 19.2 μg/ml showed 
inhibition of carrageenin-induced 
paw edema in rats; Hexane 
fraction inhibited the 
5-lipoxygenase activity (Dongmo 
et al., 2001)
Combretaceae Combretum 
molle R.Br. ex 
G.Don (6518/
SRF/CAM)
Fever, abdominal pains, 
convulsion, worm infections, 
AIDS (Bessong et al., 2004) 
Bark β-d-glucopyranosyl 2α,3 
β,6β-trihydroxy-23-
galloylolean-12-en-28-
oate (18); combregenin 
(19); arjungenin (20), 
arjunglucoside I, 
combreglucoside (Ponou 
et al., 2008)
Bark extract, compounds 18–20 
showed good activity against 
carrageenan-induced paw edema 
in rat (Ponou et al., 2008)
Crassulaceae Kalanchoe 
crenata Andr. 
(50103/YA/HNC)
Earache, smallpox, headache, 
inflammation, pain, asthma, 
palpitation, convulsion, general 
debility (Dimo et al., 2006)
Not 
specified
Not identified n-Butanol fraction inhibited 
carrageenani-, histamine-, 
serotonin-, and formalin-induced 
paw edema in rats (Dimo et al., 
2006)
Euphorbiaceae Bridelia 
scleroneura 
(42088/HNC)
Abdominal pain, contortion, 
arthritis, inflammation (Watt 
and Breyer-Brandwijk, 1962; 
Théophile et al., 2006)
Bark, 
roots
Not identified Crude bark extract showed 
peripheral and central analgesic 
and anti-inflammatory activity 
against acute inflammation 
processes in rats (Théophile et al., 
2006)
Euphorbiaceae Uapaca 
guineensis 
(41501/HNC) 
Fever, inflammation, pain, skin 
diseases, and sexual 
dysfunction (Vivien and Faure, 
1996)
Not 
specified
Not identified Bark crude extract showed 
analgesic activity, and inhibited 
carrageenan-induced 
inflammation in rats (Nkeh-
Chungag et al., 2009)
Family Speciesa Traditional treatment Plant part 
used
Bioactive (or 
potentially active) 
compoundsb
Screened activityc
Guttiferae Allanblackia 
monticola 
Staner L.C. 
(61168/HNC)
Amoebic dysentery, diarrhea, 
indigestion, pulmonary 
infections, skin diseases, 
headache, inflammation, and 
generalized pain (Raponda-
Waker and Sillans, 1961)
Bark Betulinic acid, lupeol, 
and amangostin 
(Nguemfo et al., 2009)
Crude extract from the bark, 
lupeol, betulinic acid, and 
a-mangostin inhibited paw 
carrageenan-induced edema rat 
(Nguemfo et al., 2007, 2009)
Leguminosae Erythrina 
addisoniae 
Hutchinson & 
Dalziel (41617/
HNC)
Dysentery, asthma, venereal 
diseases, boils, and leprosy 
(Talla et al., 2003)
Bark Warangalone (56) (Talla 
et al., 2003)
Bark extract and compound 56 
showed an anti-inflammatory on 
the PLA2-induced paw edema and 
12-O-tetradecanoylphorbol 
13-acetate-induced ear edema in 
mice (Talla et al., 2003)
Erythrina 
mildbraedii 
Harms (50452/
HNC)
Dysentery, stomach pains, 
venereal diseases, asthma, 
female sterility, ulcers, boils 
and various types of 
inflammations (Oliver-Bever, 
1986)
Bark, 
roots
Erycristagallin (57) 
(Njamen et al., 2003)
Root bark extract inhibited the 
carrageenan-induced mouse paw 
whilst compound 57 inhibited the 
PLA2-induced mouse paw edema 
and mouse ear edema induced by 
2-O-tetradecanoylphorbol 
13-acetate (Njamen et al., 2003)
Erythrina 
sigmoidea Hua
Female infertility, stomach pain, 
and gonorrhea (Giner-Larza 
et al., 2001)
Bark Sigmoidin A (51) and B 
(52) (Njamen et al., 
2004)
Compound 51 inhibited 
PLA2-induced paw edema in 
mice, while both compounds 51 
and 52 were found to be effective 
12-O-tetradecanoylphorbol 
13-acetate-induced ear edema 
(Njamen et al., 2004)
Millettia 
versicolor 
Welw. (32315/
HNC)
Intestine parasitosis, 
rheumatism, pain, infertility 
(Adjanohoun et al., 1988; 
Bouquet, 1969)
Not 
specified
2-acetyl-7-
methoxynaphthol[2,3-b]
furan-4,9-quinone (29) 
(Fotsing et al., 2003)
CH2Cl2 fraction from methanol 
crude bark extract inhibited 
carrageenan-induced paw edema 
and TPA-induced acute ear edema 
in mouse as well as compound 29 
(Fotsing et al., 2003)
Millettia 
griffoniana Baill. 
(32315/SRF/
HNC)
Boils, insects bits, 
inflammatory affections like 
pneumonia, and asthma, 
infertility, amenorrhea, 
menopausal disorders 
(Sandberg and Cronlund, 1977)
Bark, 
roots
griffonianone D (55) 
(Yankep et al., 2003)
Extract of the root bark and 
compound 55 showed anti-
inflammatory effects via inhibition 
of PLA2-induced mouse paw 
edema and TPA-induced acute 
mouse ear edema (Yankep et al., 
2003)
Solanaceae Solanum 
torvum Swartz. 
(21103/HNC)
Fever, wounds, tooth decay, 
haemostatic properties, pain, 
anti-inflammation (Henty, 1973; 
Ndebia et al., 2007)
Leaves Not identified Crude extract from the leaves 
inhibits both acetic acid- and 
pressure-induced pain at 300 mg/
kg body weight of rats, and also 
anti-inflammatory activity on 
carrageenan-induced paw edema 
(Ndebia et al., 2007
aHNC or SRFK: Cameroon National herbarium code.
bCompounds characterized for the first time in Cameroonian medicinal plant are underlined.
cScreened activity: TPA (2-O-tetradecanoylphorbol 13-acetate); PLA2 (phospholipase A2).
Table 4 | Plants used in Cameroon as anti-inflammatory and analgesic agents, with evidence of their activities. Table 4 | Continued
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Family Speciesa Traditional treatment Plant part 
used
Bioactive (or 
potentially active) 
compoundsb
Screened activityc
Acanthaceae Acanthus 
montanus 
(Nees) T. 
Anderson 
(1652/
SRF61CAM)
Cough, hypertension, skin 
infection, boil, witches, 
dysmenorrhoea, pain, epilepsy, 
miscarriages, heart troubles, 
rheumatic pain, syphilis (Burkill, 
1985; Adjanohoun et al., 1996; 
Babu et al., 2001; Noumi and 
Fozi, 2003; Igoli et al., 2005; 
Nana et al., 2008)
Leaves Not identified Leave extract showed analgesic 
and anti-inflammatory properties 
and the proposed mechanism 
was the inhibition of the 
prostaglandins pathway at 
200 mg/kg in rats. Also, this 
extract at 200 mg/kg body weight 
in rats reduced carrageenan-
induced edema, and formalin-
induced pain (Asongalem et al., 
2004).
Anacardiaceae Sclerocarya 
birrea (A. Rich.) 
Hochst (7770/
HNC)
Boils and blood circulation 
problems, rheumatism, 
infectious diseases, 
inflammation (Mojeremane and 
Tshwenyane, 2004; Fotio et al., 
2009)
Bark Not identified Bark extract inhibited albumin-
induced paw edema (Ojewole, 
2004), Formalin- or Freund’s 
adjuvant (CFA)-carrageenan-, 
histamine, or serotonin-induced 
paw edema (Fotio et al., 2009) in 
rats
Caesalpiniaceae Erythrophleum 
suaveolens, 
Guillemin & 
Perrottet 
(HN001AD)
Anti-poison, dermatitis, 
infectious disease, convulsion, 
inflammation due to snake bite, 
cardiac problems, headaches, 
migraines edema, rheumatism, 
asthma (Dalziel, 1937; 
Bouquet, 1969; Leiderer, 1982; 
Neuwinger, 1998)
Bark Not identified Extract from the bark and 
fractions at 19.2 μg/ml showed 
inhibition of carrageenin-induced 
paw edema in rats; Hexane 
fraction inhibited the 
5-lipoxygenase activity (Dongmo 
et al., 2001)
Combretaceae Combretum 
molle R.Br. ex 
G.Don (6518/
SRF/CAM)
Fever, abdominal pains, 
convulsion, worm infections, 
AIDS (Bessong et al., 2004) 
Bark β-d-glucopyranosyl 2α,3 
β,6β-trihydroxy-23-
galloylolean-12-en-28-
oate (18); combregenin 
(19); arjungenin (20), 
arjunglucoside I, 
combreglucoside (Ponou 
et al., 2008)
Bark extract, compounds 18–20 
showed good activity against 
carrageenan-induced paw edema 
in rat (Ponou et al., 2008)
Crassulaceae Kalanchoe 
crenata Andr. 
(50103/YA/HNC)
Earache, smallpox, headache, 
inflammation, pain, asthma, 
palpitation, convulsion, general 
debility (Dimo et al., 2006)
Not 
specified
Not identified n-Butanol fraction inhibited 
carrageenani-, histamine-, 
serotonin-, and formalin-induced 
paw edema in rats (Dimo et al., 
2006)
Euphorbiaceae Bridelia 
scleroneura 
(42088/HNC)
Abdominal pain, contortion, 
arthritis, inflammation (Watt 
and Breyer-Brandwijk, 1962; 
Théophile et al., 2006)
Bark, 
roots
Not identified Crude bark extract showed 
peripheral and central analgesic 
and anti-inflammatory activity 
against acute inflammation 
processes in rats (Théophile et al., 
2006)
Euphorbiaceae Uapaca 
guineensis 
(41501/HNC) 
Fever, inflammation, pain, skin 
diseases, and sexual 
dysfunction (Vivien and Faure, 
1996)
Not 
specified
Not identified Bark crude extract showed 
analgesic activity, and inhibited 
carrageenan-induced 
inflammation in rats (Nkeh-
Chungag et al., 2009)
Family Speciesa Traditional treatment Plant part 
used
Bioactive (or 
potentially active) 
compoundsb
Screened activityc
Guttiferae Allanblackia 
monticola 
Staner L.C. 
(61168/HNC)
Amoebic dysentery, diarrhea, 
indigestion, pulmonary 
infections, skin diseases, 
headache, inflammation, and 
generalized pain (Raponda-
Waker and Sillans, 1961)
Bark Betulinic acid, lupeol, 
and amangostin 
(Nguemfo et al., 2009)
Crude extract from the bark, 
lupeol, betulinic acid, and 
a-mangostin inhibited paw 
carrageenan-induced edema rat 
(Nguemfo et al., 2007, 2009)
Leguminosae Erythrina 
addisoniae 
Hutchinson & 
Dalziel (41617/
HNC)
Dysentery, asthma, venereal 
diseases, boils, and leprosy 
(Talla et al., 2003)
Bark Warangalone (56) (Talla 
et al., 2003)
Bark extract and compound 56 
showed an anti-inflammatory on 
the PLA2-induced paw edema and 
12-O-tetradecanoylphorbol 
13-acetate-induced ear edema in 
mice (Talla et al., 2003)
Erythrina 
mildbraedii 
Harms (50452/
HNC)
Dysentery, stomach pains, 
venereal diseases, asthma, 
female sterility, ulcers, boils 
and various types of 
inflammations (Oliver-Bever, 
1986)
Bark, 
roots
Erycristagallin (57) 
(Njamen et al., 2003)
Root bark extract inhibited the 
carrageenan-induced mouse paw 
whilst compound 57 inhibited the 
PLA2-induced mouse paw edema 
and mouse ear edema induced by 
2-O-tetradecanoylphorbol 
13-acetate (Njamen et al., 2003)
Erythrina 
sigmoidea Hua
Female infertility, stomach pain, 
and gonorrhea (Giner-Larza 
et al., 2001)
Bark Sigmoidin A (51) and B 
(52) (Njamen et al., 
2004)
Compound 51 inhibited 
PLA2-induced paw edema in 
mice, while both compounds 51 
and 52 were found to be effective 
12-O-tetradecanoylphorbol 
13-acetate-induced ear edema 
(Njamen et al., 2004)
Millettia 
versicolor 
Welw. (32315/
HNC)
Intestine parasitosis, 
rheumatism, pain, infertility 
(Adjanohoun et al., 1988; 
Bouquet, 1969)
Not 
specified
2-acetyl-7-
methoxynaphthol[2,3-b]
furan-4,9-quinone (29) 
(Fotsing et al., 2003)
CH2Cl2 fraction from methanol 
crude bark extract inhibited 
carrageenan-induced paw edema 
and TPA-induced acute ear edema 
in mouse as well as compound 29 
(Fotsing et al., 2003)
Millettia 
griffoniana Baill. 
(32315/SRF/
HNC)
Boils, insects bits, 
inflammatory affections like 
pneumonia, and asthma, 
infertility, amenorrhea, 
menopausal disorders 
(Sandberg and Cronlund, 1977)
Bark, 
roots
griffonianone D (55) 
(Yankep et al., 2003)
Extract of the root bark and 
compound 55 showed anti-
inflammatory effects via inhibition 
of PLA2-induced mouse paw 
edema and TPA-induced acute 
mouse ear edema (Yankep et al., 
2003)
Solanaceae Solanum 
torvum Swartz. 
(21103/HNC)
Fever, wounds, tooth decay, 
haemostatic properties, pain, 
anti-inflammation (Henty, 1973; 
Ndebia et al., 2007)
Leaves Not identified Crude extract from the leaves 
inhibits both acetic acid- and 
pressure-induced pain at 300 mg/
kg body weight of rats, and also 
anti-inflammatory activity on 
carrageenan-induced paw edema 
(Ndebia et al., 2007
aHNC or SRFK: Cameroon National herbarium code.
bCompounds characterized for the first time in Cameroonian medicinal plant are underlined.
cScreened activity: TPA (2-O-tetradecanoylphorbol 13-acetate); PLA2 (phospholipase A2).
Table 4 | Plants used in Cameroon as anti-inflammatory and analgesic agents, with evidence of their activities. Table 4 | Continued
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reported to be useful in diabetes worldwide and have empirically 
been used as anti-diabetic and anti-hyperlipidemic remedies. Anti-
hyperglycemic effects of these plants were attributed to their ability 
to restore the function of pancreatic tissues by increasing insulin 
output, inhibiting the intestinal absorption of glucose, or enhancing 
metabolism of insulin-dependent processes. Several plant prepara-
tions were traditionally used in Cameroon to treat diabetes. Some 
of them were screened for their bioactivity, but most of the studies 
were not pursued until the isolation of active principles. Plants 
with hypoglycaemic activities include Anacardium occidentale, 
Sclerocarya birrea, Ageratum conyzoides, Ceiba pentandra, Kalanchoe 
crenata, Bridelia ndellensis, Irvingia gabonensis, Bersama engleriana 
and Morinda lucida (Table 5).
antioxidant activities
The common link between oxidants and inflammatory reactions, 
infections, cancer, and other disorders has been well established 
(Mongelli et al., 1997; Wang et al., 1999). However, this may not 
really be of therapeutic relevance, but more of a preventive medi-
cine. In chronic infections and inflammation as well as in other 
disorders, release of leukocytes and other phagocytic cells readily 
defends the organism from further injury. The cells do this by 
releasing free oxidant radicals, and these by-products are gener-
ally reactive oxygen species (ROS) such as super oxide anion, 
hydroxyl radical, nitric oxide, and hydrogen peroxide that result 
from cellular redox processes (Ames et al., 1993; Mongelli et al., 
1997). At low or moderate concentrations, ROS exert beneficial 
effects on cellular responses and immune function. At high levels, 
however, free radicals and oxidants generate oxidative stress, a 
deleterious process that can damage cell structures, including 
lipids, proteins, and DNA (Pham-Huy et al., 2008). Oxidative 
stress plays a major role in the development of chronic and 
degenerative ailments such as cancer, autoimmune disorders, 
rheumatoid arthritis, cataract, aging, cardiovascular, and neu-
rodegenerative diseases (Willcox et al., 2004b; Pham-Huy et al., 
2008). Antioxidants act as free radical scavengers by prevent-
ing and repairing damages caused by ROS and, therefore, can 
enhance the immune defense and lower the risk of cancer and 
degenerative diseases (Ames et al., 1993; Pham-Huy et al., 2008). 
In recent years, there is an increasing interest in finding antioxi-
dant phytochemicals, because they can inhibit the propagation of 
free radical reactions, and thereby protect the human body from 
diseases (Terao and Piskula, 1997). Several medicinal plants of 
Cameroon were screened for their antioxidant properties and a 
number of bioactive compounds was isolated (Table 6). Omisore 
et al. (2005) considered the cut-off point for antioxidant activ-
ity as 50 μg/ml. Samples with IC
50
 > 50 μg/ml were classified as 
being moderately active, while samples with IC
50
 < 50 μg/ml were 
judged as having high antioxidant capacity. In the present paper, 
samples will be considered to have high or significant antioxidant 
capacity with IC
50
 < 50 μg/ml (extract) or IC
50
 < 10 μg/ml (com-
pounds), moderate antioxidant capacity with 50 < IC
50
 < 100 μg/
ml (extract) or 10 < IC
50
 < 20 μg/ml (compounds) and low anti-
oxidant capacity with IC
50
 > 100 μg/ml (extract) or IC
50
 > 20 μg/
ml (compounds). Extracts from 42 medicinal plants of Cameroon 
used for the treatment of anemia, diabetes, AIDS, malaria, and 
obesity were recently screened for antioxidant properties, with 
a considerable number  showing good activities (Agbor et al., 
2007). Many of them exhibited high inhibition percentages on 
the basis of Folin, Ferric reducing antioxidant power (FRAP), 
and DPPH (1,1-diphenyl-2-picrylhydrazyl) assays. Plants with 
good activities included Alchornea cordifolia (Euphorbiaceae), 
Dacryodes edulis (Burseraceae), Ocimum basilicum (Lamiaceae), 
Harungana madagascariensis (Hypericaceae), Cylicodiscus gabun-
ensis (Mimosaceae), Coleus coprosifolius (Lamiaceae) (Agbor et al., 
2007). Arylbenzofurans isolated from the bark of Morus mesozygia 
(Moraceae), moracin T (43), moracin U (44), moracin S (45); 
moracin R (46) also showed strong DPPH scavenging capability 
with IC
50
 values of 4.12, 5.06, 6.08, and 7.17 μg/ml, respectively 
(Kapche et al., 2009). The activity of the crude extract of this plant 
was also reported as significant (IC
50
: 5.92 μg/ml), by means of 
the DPPH scavenging assay (Kapche et al., 2009).
other activities
Other studies involving Cameroon medicinal plants include their 
action on human fertility and enzymatic activities. However, few 
studies have focused on these activities, explaining the scarcity of 
published data.
Some plants with positive effects on the reproductive system 
based on studies using experimental rats have been reported. They 
include Aloe buettneri (Liliaceae), Justicia insularis and Dicliptera 
verticillata (Acanthaceae) and Hibiscus macranthus (Malvaceae), 
locally used to regulate the menstrual cycle and to treat dys-
menorrhea or infertility in women (Telefo et al., 1998); Basella 
alba (Basellaceae) (Moundipa et al., 2005), and Mondia whitei 
(Periplocaceae) traditionally claimed to increase libido (Watcho 
et al., 2001).
Some compounds from Cameroonian plants were investigated 
for the ability to interfere with the activity of some enzymes such 
as xanthine oxidase, phosphodiesterase I, or prolyl endopeptidase. 
Xanthine oxidase catalyzes the oxidative hydroxylation of hypox-
anthine or xanthine using oxygen as a cofactor, and the result-
ing end products are superoxide anion (O
2
•−) and uric acid. The 
inhibitors of xanthine oxidase enzyme can prevent the generation 
of excess superoxide anions (Chung et al., 1997). Phosphodiesterase 
I successively hydrolyzes 5′-mononucleotides from 3′-hydroxyl-
terminated ribo- and deoxyribo-oligonucleotides. The enzyme has 
been widely utilized as a tool for structural and sequential studies 
of nucleic acids. The 5′-nucleotide phosphodiesterase isozyme-V 
test is useful in detecting liver metastatis in breast, gastrointestinal, 
lung, and various other forms of cancers (Lei-Injo et al., 1980). 
Prolyl endopeptidase catalyzes the hydrolysis of peptide bonds at 
the l-proline carboxy terminal and, thus, plays an important role in 
the biological regulation of proline-containing neuropeptides and 
peptide hormones, which are recognized to be involved in learning 
and memory (Szeltner et al., 2000). The stilbene glycosides  isolated 
from Boswellia papyrifera (Del.) Hochst (Burseraceae),  trans-4′,5-
dihydroxy-3-methoxystilbene-5-O-{α-l-rhamnopyranosyl-(1-2)- 
[α-l-rhamnopyranosyl-(1-6)]-β-d-glucopyranoside and  trans-4′, 
5-dihydroxy-3-methoxystilbene-5-O-[α-l-rhamnopyranosyl-
(1-6)]-β-d-glucopyranoside exhibited significant inhibition of 
phosphodiesterase I and xanthine oxidase (Atta-ur-Rahman 
et al., 2005). Triterpenes such as 3-α-acetoxy-27-hydroxylup-
20(29)-en-24-oic acid, 11-keto-β-boswellic acid, β-elemonic 
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Family Speciesa Traditional treatment Plant part 
used
Bioactive (or potentially 
active) compoundsb
Screened activityc
Ebenaceae Diospyros 
sanza-minika A. 
Chevalier (9649/
SRFCam)
Epilepsy, paralysis, 
convulsions, spasm, pains 
(Burkill, 1985)
Leaves 11-O-p-
hydroxybenzoylnorbergenin; 
4-O-(30-methylgalloyl)
norbergenin; 4-O-
syringoylnorbergenin; 
norbergenin; 4-O-
galloylnorbergenin; quercitol 
(Tangmouo et al., 2009)
DPPH scavenging activity: 
significant for 4-O-
galloylnorbergenin, moderate for 
norbergenin, 11-O-p-
Hydroxybenzoylnorbergenin, 
4-O-(30-Methylgalloyl)norbergenin 
and 4-O-Syringoylnorbergenin 
(Tangmouo et al., 2009)
Guttiferae Garcinia 
polyantha Oliv 
(1337/SRF/Cam)
Dressing for wounds 
(Bouquet, 1969)
Sap Bangangxanthone A; 
bangangxanthone B; 
2-hydroxy-1,7-
dimethoxyxanthone; 
1,5-dihydroxyxanthone 
(Lannang et al., 2005)
DPPH scavenging activity: 
bangangxanthone A isolated from 
the bark showed the best activity 
with an IC50 = 87.0 μM while the 
standard value for BHA was 
IC50 = 42.0 μM (Lannang et al., 
2005)
Garcinia afzelii 
Engl.
Bacterial infections, dental 
caries (Adu-Tutu et al., 
1979; Waffo et al., 2006)
Leaves; 
flowers
Afzeliixanthones A; 
afzeliixanthones B (Waffo 
et al., 2006)
DPPH scavenging activity: 
Significant for the crude extract and 
moderate for Afzelii xanthones A 
and B (Waffo et al., 2006)
Hypericaceae Harungana 
madagascariensis 
Lam. (32358/
HNC)
Diarrhea, dysentery, 
indigestion, poor 
pancreatic function 
(Berhaut, 1975; Prajapati 
et al., 2003)
Not 
specified
Harunmadagascarins A and 
Harunmadagascarins B, 
harunganol B and harungin 
anthrone (Kouam et al., 2005)
DPPH scavenging activity: IC50 of 
60.97; 64.76 were recorded with 
harunmadagascarin and harunganol 
B respectively (Kouam et al., 2005)
Meliaceae Carapa grandiflora 
sprsgue
Arthritis, general fatigue, 
skin diseases and as 
febrifuge (Ayafor et al., 
1994)
Seeds Quercitrin (Omisore et al., 
2005)
DPPH scavenging activity: low for 
quercetin (Omisore et al., 2005)
Mimosaceae Entada rheedii 
Spreng (19966/
SRI/CAM)
Jaundice (Nzowa et al., 
2010)
Seeds Rheediinoside A; rheediinoside 
B (Nzowa et al., 2010)
ABTS·+ scavenging activity: 
moderate for rheediinoside B; low 
for rheediinoside A; DPPH 
scavenging activity: low activity for 
rheediinoside A and rheediinoside B 
(Nzowa et al., 2010)
Moraceae Dorstenia 
convexa De Wild 
(53450 HNC)
Malaria (Boyom et al., 
2009)
Twigs Bartericins A; stigmasterol; 
isobavachalcone (Omisore 
et al., 2005)
DPPH scavenging activity: low 
bartericin A and isobavachalcone 
and stigmasterol (Omisore et al., 
2005)
Dorstenia barteri 
Bureau (44016/
HNC)
Snakebite, rheumatic, 
infectious diseases, 
arthritis (Tsopmo et al., 
1999)
Whole 
plant
Bartericins A, and B; 
stigmasterol; isobavachalcone; 
4-hydroxylonchocarpin 
(Omisore et al., 2005)
DPPH scavenging activity: 
significant for twigs extract 
(Omisore et al., 2005)
Dorstenia mannii 
Hook. f. (2135/
HNC)
Rheumatism, stomach 
disorders (Bouquet, 1969)
Leaves Dorsmanin F; 6,8-
diprenyleridictyol (Omisore 
et al., 2005)
DPPH scavenging activity: low for 
6,8-diprenyleriodictyol, and 
dosrmanin F (Omisore et al., 2005)
Morus mesozygia 
Stapf. (4228/
SRFK)
Arthritis, rheumatism, 
malnutrition, debility, 
pain-killers, stomach 
disorders, wound 
infections, gastroenteritis, 
peptic ulcer, infectious 
diseases (Burkill, 1985; 
Noumi and Dibakto, 2002)
Bark Moracin R (46); moracin S (45); 
moracin T (43); moracin U (44) 
(Kapche et al., 2009)
DPPH scavenging activity: 
significant for bark crude extract, 
compounds 43–46 (Kapche et al., 
2009)
(Continued)
Table 6 | Plants used in Cameroon with evidence of their as antioxidant activities.
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acid, 3 α-acetoxy-11-keto-β-boswellic acid, and β-boswellic acid 
also exhibited prolyl endopeptidase inhibitory activities (Atta-ur-
Rahman et al., 2005).
conclusion
The present review presents an overview of medicinal plants 
research in Cameroon and is intended to serve as scientific base-
line information for the documented plants as well as a starting 
point for future studies. The paper draws attention on some active 
metabolites and plant extracts, with the potential for new drugs or 
improved plant medicines. The review inevitably shows the richness 
of the Cameroon flora as medicinal resource and demonstrates the 
effectiveness of numerous traditionally used plants. Presently, there 
is an urgent necessity for standardization of plant-derived drugs, 
as their use is still empirical. There is also an urgent requirement 
to standardize methods and cut-off points for describing their 
bioactivities. Other recommendations include parallel screenings 
by using cytotoxicity tests to preclude non-specific cytotoxicity 
from being interpreted as efficient following in vitro screening. 
The elucidation of the mechanisms of action of biologically active 
extracts and compounds should be strengthened and given prior-
ity in future investigations as already shown for natural products 
from other parts of the world (Kong et al., 2009; Youns et al., 2010; 
Konkimalla and Efferth, 2010).
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